Evaluation of HBs Ag, HCV and HIV Ag-Ab Assays using Bio-Rad Elite Microplate Analyzer

Sang-Hyun Hwang; Heung-Bum Oh; Hyon-Suk Kim; Eun Yup Lee

doi:10.3343/kjlm.2006.26.6.436

Journal List > Korean J Lab Med > v.26(6) > 1011357

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Hwang, Oh, Kim, and Lee: Evaluation of HBs Ag, HCV and HIV Ag-Ab Assays using Bio-Rad Elite Microplate Analyzer

Original Article

Korean J Leg Med 2006;26(6):436-441.

Published online: 10 February 2006

DOI: https://doi.org/10.3343/kjlm.2006.26.6.436

Evaluation of HBs Ag, HCV and HIV Ag-Ab Assays using Bio-Rad Elite Microplate Analyzer

Sang-Hyun Hwang, M.D.¹, Heung-Bum Oh, M.D.², Hyon-Suk Kim, M.D.³, Eun Yup Lee, M.D.¹

¹Department of Laboratory Medicine, Pusan National University School of Medicine, Busan, Korea

²Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea

³Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea

Received 7 August 2006 Revised 25 October 2006 Accepted 12 November 2006

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

In this study, we evaluated the performance of Elite microplate analyzer (Bio-Rad Laboratories, France) and the related assays (ULTRA line) for the detection of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Methods

Seroconversion panels, HBsAg positive/HBsAg negative (n=99/n=1,422), anti-HCV positive/negative (n=97/n=1,670), and anti-HIV positive/negative (n=112/n=1,704) samples were used to evaluate the performance of Monolisa HBsAg ULTRA, Monolisa HCV Ag-Ab ULTRA, and Genscreen ULTRA HIV Ag-Ab, respectively. The agreement of Elite microplate analyzer with CODA analyzer (Bio-Rad Laboratories, CA, USA) was also evaluated.

Results

The detection limit of Monolisa HBsAg ULTRA was 0.034 IU/mL. For Monolisa HBsAg ULTRA, Monolisa HCV Ag-Ab ULTRA, and Genscreen ULTRA HIV Ag-Ab, diagnostic sensitivities were all 100%, diagnostic specificities were 100%, 99.8% and 99.9%, and total CVs (coefficients of variation) were 13.8–17.5%, 3.4–5.2%, and 7.5–9.5%, respectively. The agreement of Elite microplate analyzer with CODA analyzer was 99.5%.

Conclusions

The performance of Elite microplate analyzer and the related assays on analytical sensitivity, precision, early detection, diagnostic sensitivity and specificity was all adequate for a mass screening. However, further large multi-center studies should be performed to validate our results.

Keywords: Hepatitis B virus, Hepatitis C virus, Human immunodeficiency virus, Evaluation, Sensitivity, Specificity, Elite Microplate Analyzer

References

1. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of clinical chemistry devices; Approved guideline. Document EP5-A.Vilanova, Pa: National Committee for Clinical Laboratory Standards;1999.

2. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159–74.

3. Hoofnagle JH. Posttransfusion hepatitis B. Transfusion. 1990; 30:384–6.

4. Weber B, Muhlbacher A, Melchior W. Detection of an acute asymptomatic HBsAg negative hepatitis B virus infection in a blood donor by HBV DNA testing. J Clin Virol. 2005; 32:67–70.

5. Matsumoto C, Tadokoro K, Fujimura K, Hirakawa S, Mitsunaga S, Juji T. Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository. Transfusion. 2001; 41:878–84.

6. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996; 334:1685–90.

7. Seo DH. Transfusion-transmitted diseases: current state and recent countermeasures. J Korean Med Assoc. 2006; 49:410–5.

8. Carman WF, Van Deursen FJ, Mimms LT, Hardie D, Coppola R, Decker R, et al. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology. 1997; 26:1658–66.

9. Howard CR. The structure of hepatitis B envelope and molecular variants of hepatitis B virus. J Viral Hepat. 1995; 2:165–70.

10. Weber B, Dengler T, Berger A, Doerr HW, Rabenau H. Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBs-Ag. J Clin Microbiol. 2003; 41:135–43.

11. Weber B, Van der Taelem-Brule N, Berger A, Simon F, Geudin M, Ritter J. Evaluation of a new automated assay for hepatitis B surface antigen (HBsAg) detection VIDAS HBsAg Ultra. J Virol Methods. 2006; 135:109–17.

12. Weber B, Bayer A, Kirch P, Schluter V, Schlieper D, Melchior W. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol. 1999; 37:2639–47.

13. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods. 2004; 115:217–22.

14. Howard CR, Allison LM. Hepatitis B surface antigen variation and protective immunity. Intervirology. 1995; 38:35–40.

15. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol. 1999; 59:19–24.

16. Louisirirotchanakul S, Kanoksinsombat C, Theamboonlert A, Puthavatana P, Wasi C, Poovorawan Y. Mutation of the “a” determinant of HBsAg with discordant HBsAg diagnostic kits. Viral Immunol. 2004; 17:440–4.

17. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, et al. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion. 1998; 38:56–9.

18. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005; 32:102–12.

19. Weber B. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol. 2006; 78(S1):):S59–65.

20. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Ferey MP, Ebel A, et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol. 2006; 44:2321–6.

21. van Helden J, Denoyel GA. Experience with the IVDD performance evaluations of the ADVIA Centaur infectious disease assays. J Clin Virol. 2004; 30:S16–8.

22. Hennig H, Schlenke P, Kirchner H, Bauer I, Schulte-Kellinghaus B, Bludau H. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods. 2000; 84:181–90.

23. Schappert J, Wians FH Jr, Schiff E, Smalley D, Gambardella R, Lee WM, et al. Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay. Clin Chim Acta. 2006; 372:158–66.

24. Sickinger E, Stieler M, Kaufman B, Kapprell HP, West D, Sandridge A, et al. Multicenter evaluation of a new, automated enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies and antigen. J Clin Microbiol. 2004; 42:21–9.

25. Kang HJ, Yoo KH, Kim HS, Cho HC. Evaluation of Abbott fourth generation HIV antigen and antibody assays. Korean J Lab Med. 2006; 26:39–44.

26. Laperche S, Bouchardeau F, Maniez M, Beolet M, Elghouzzi MH, Lefrere JJ. Nucleic acid testing in blood donations reactive to hepatitis C virus antibody, but with an extremely low viral load. Vox Sang. 2004; 86:198.

27. Jonas G, Pelzer C, Beckert C, Hausmann M, Kapprell HP. Performance characteristics of the ARCHITECT anti-HCV assay. J Clin Virol. 2005; 34:97–103.

28. Kwon JA, Yoon SY, Lee CK, Lim CS, Lee KN, Sung HJ, et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods. 2006; 133:20–6.

29. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005; 85:257–68.

Table 1.

Low detection limit of Monolisa HBsAg ULTRA test for HBsAg WHO standard material

WHO standard (IU/mL)	1st replicate		2nd replicate		3rd replicate		4th replicate
WHO standard (IU/mL)	S/C Ratio	Result	S/C Ratio	Result	S/C Ratio	Result	S/C Ratio	Result
3.3	40.9	P	38.9	P	46.3	P	43.8	P
0.33	6.4	P	6.1	P	6.6	P	6.8	P
0.1	2.3	P	2.4	P	2.4	P	2.3	P
0.075	2.2	P	2.2	P	2.6	P	2.4	P
0.05	1.2	P	1.7	P	1.2	P	1.2	P
0.025	0.6	N	0.7	N	0.7	N	0.7	N
0.0125	0.4	N	0.5	N	0.5	N	0.5	N

Abbreviations: P, positive; N, negative; S/C, signal/cut-off ratio.

Table 2.

Precision performance of Bio-Rad ULTRA line kits on Elite microplate system

Item	HBsAg		HCV Ag-Ab			HIV Ag-Ab
level	1	2	1	2	3	1	2
Mean S/C	1.2	11.6	1.8	2.7	6.2	1.9	5.3
Within-run CV	7.2	5.0	3.8	2.5	1.5	2.0	4.5
Between-run CV	13.7	5.4	0.7	4.2	1.2	3.9	2.2
Between-day CV	8.2	11.7	3.5	2.3	2.8	6.1	8.0
Total CV (%)	17.5	13.8	5.2	5.4	3.4	7.5	9.5

Abbreviations: S/C, signal/cut-off ratio; CV, coefficient of variation.

Table 3.

Comparison of the performance of Elite microplate system, Abbott Prism and Abbott AxSYM version 2 in seroconversion panels

Panel serial No.	Days since 1st bleed	Elite microplate (S/C ratio)	Abbott Prism^* (S/C ratio)	Abbott AxSYM version 2^* (S/C ratio)
HBV BBI
PHM935A–02	2	0.1	0.5	0.4
PHM935A–03	7	0.2	0.7	0.4
PHM935A–04	9	0.2	0.3	0.4
PHM935A–05	14	0.1	0.4	0.4
PHM935A–06	16	0.2	0.6	0.4
PHM935A–07	21	1.5	1.8	0.7
HCV BBI
PHV916–02	2	0.6	0.1	0.4
PHV916–03	7	0.1	0.1	0.3
PHV916–04	9	1.0	0.2	0.4
PHV916–05	16	0.8	1.0	0.2
PHV916–06	19	2.2	1.9	4.4
PHV916–07	23	3.4	2.7	15.5
HIV BBI
PRB931–02	2	0.4	0.3	0.4
PRB931–03	7	0.4	0.4	0.3
PRB931–04	9	0.5	0.3	0.4
PRB931–05	15	0.9	0.3	0.4
PRB931–06	28	37.8	7.0	7.5
PRB931–07	33	37.8	64.9	14.2

^* Information was obtained from seroconversion panel data sheets.

Table 4.

Summary of the diagnostic sensitivity and specificity of Bio-Rad Monolisa HBsAg, HCV Ag-Ab, and Genscreen HIV Ag-Ab ULTRA kits on Elite microplate system

Performance item	Test item	Test sample number	Elite microplate		Performance (95%CI)
Performance item	Test item	Test sample number	Positive	Negative	Performance (95%CI)
Diagnostic sensitivity	HBsAg	99	99	0	100%
					(96.3–100%)
	HCV Ab	97	97	0	100%
					(96.2–100%)
	HIV Ab	112	112	0	100%
					(96.7–100%)
Diagnostic specificity	HBsAg	1,400	0	1,400	100%
					(99.7–100%)
	HCV Ab	1,670	4	1,666	99.8%
					(99.4–99.9%)
	HIV Ab	1,704	1	1,703	99.9%
					(99.7–99.9%)

Abbreviation: CI, confidence interva.

Table 5.

Comparison of anti-HCV results of LG HCV Ab 3.0 EIA test kit (LG chemicals, Seoul, Korea) performed on the different automatic analyzers, CODA system and Elite microplate system

		LG HCV Ab test on Elite system		Total	Kappa^†
		Positive	Negative	Total	Kappa^†
LG HCV Ab test on CODA system	Positive	30	6^*	36	0.88
	Negative	2^*	1,494	1,496
Total		32	1,500	1,532

^* Eight discrepant results were confirmed as all negative by RIBA test.

^† Standards for strength of agreement for the kappa coefficient: ≤0=poor, 0.01–0.20=slight, 0.21–0.40=fair, 0.41–0.60=moderate, 0.61–0.80=substantial, and 0.81–1.0=almost perfect[29].

TOOLS

Similar articles